STOCK TITAN
  1. Home
  2. News
  3. BTAX

BIOSTAX CORP - $BTAX STOCK NEWS

Welcome to our dedicated page for BIOSTAX news (Ticker: $BTAX), a resource for investors and traders seeking the latest updates and insights on BIOSTAX stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIOSTAX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIOSTAX's position in the market.

News
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception
Rhea-AI Summary
Biostax Corp. (BTAX) proudly announces its participation in the U.S. Business Action to End HIV Annual Coalition Meeting and the World AIDS Day Reception. The company's commitment to driving accelerated progress toward ending HIV is evident through its collaboration, innovation, and collective efforts. The expanded board brings fresh perspectives and strategic insights, unlocking new opportunities for Biostax Corp. to contribute significantly to the global effort against HIV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.29%
Tags
conferences
-
News
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro
Rhea-AI Summary
Biostax Corp (BTAX) announces the appointment of Influential Business Leader Roger “Craig” Suro, a renowned Virginia native with a track record in business innovation, public policy, and community revitalization. Mr. Suro's expertise in driving capital, innovation, and funding for transformative projects is expected to amplify Biostax's growth trajectory, bringing unparalleled opportunities and increased funding avenues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15%
Tags
management
-
News
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors
Rhea-AI Summary
Biostax Corp announces the appointment of Clay Caperton to its Board of Directors. Caperton has a rich history in sports management and the not-for-profit sector. She has a track record of securing substantial financial contributions and cultivating donor networks. Biostax expects her to enhance fundraising initiatives and foster valuable relationships for unprecedented growth and impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News
Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment
Rhea-AI Summary
Biostax Corp announces milestone in rebranding initiative, changes name to Biostax and ticker symbol to BTAX. Company focuses on substance abuse solutions and HIV treatment, aiming to address global challenges and improve health outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
none
Stock BTAX logo
BIOSTAX CORP

OTC:BTAX

BTAX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BTAX Stock Data

3.95M
35.88M
71.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Winter Park

About BTAX

immune therapeutics is a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of our novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. company’s technology platform is built on two different immunotherapies, low dose naltrexone (ldn) and methionine-enkephalin (menk). both therapies have been decades in the making at institutions such as the pennsylvania state university medical school at hershey, university of chicago, state university of new york, and multiple sclerosis center at ucsf.